Mauna Kea Technologies Announces 7 Presentations Highlighting the Clinical Value of Cellvizio in Gastrointestinal Diseases at Digestive Disease Week (DDW) 2021 Virtual
Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the presentation of 7 abstracts supporting Cellvizio at Digestive Disease Week (DDW) 2021 Virtual, being held May 21-23. These abstracts focus on Barrett s esophagus (BE), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and associated food allergies, pancreatic cysts and other gastrointestinal diseases. Studies are focused on how the use of Cellvizio potentially impacts patient management and improves outcomes.